Cargando…
Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease
Nonalcoholic fatty liver disease (NAFLD), also named metabolic dysfunction-associated fatty liver disease (MAFLD), is a progressive disease spectrum encompassing simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. It is a clinically silent disease leading to multiple extr...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242599/ https://www.ncbi.nlm.nih.gov/pubmed/35783879 http://dx.doi.org/10.7759/cureus.25495 |
_version_ | 1784738088402026496 |
---|---|
author | Hassen, Gashaw Singh, Abhishek Belete, Gizeshwork Jain, Nidhi De la Hoz, Ivonne Camacho-Leon, Genesis P Dargie, Nitsuh K Carrera, Keila G Alemu, Tadesse Jhaveri, Sharan Solomon, Nebiyou |
author_facet | Hassen, Gashaw Singh, Abhishek Belete, Gizeshwork Jain, Nidhi De la Hoz, Ivonne Camacho-Leon, Genesis P Dargie, Nitsuh K Carrera, Keila G Alemu, Tadesse Jhaveri, Sharan Solomon, Nebiyou |
author_sort | Hassen, Gashaw |
collection | PubMed |
description | Nonalcoholic fatty liver disease (NAFLD), also named metabolic dysfunction-associated fatty liver disease (MAFLD), is a progressive disease spectrum encompassing simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. It is a clinically silent disease leading to multiple extra-hepatic complications/comorbidities. It is an independent risk factor for cardiovascular disease (CVD), increasing susceptibility to hypertension, atherosclerosis, arrhythmia, myocardial dysfunction, cardiac valve deformation, and venous thrombosis through putative mechanisms including systemic inflammation, endothelial dysfunction, oxidative stress, insulin resistance, and altered lipid metabolism. Eventually, it increases the CVD prevalence, incident, and fatality, contributing to a huge health care burden. In fact, CVD is becoming the leading cause of mortality among patients with NAFLD. Other cardiometabolic risk factors coexisting with NAFLD may also accelerate the synergistic development of CVD, which warrants assessment targeting hypertension, diabetes mellitus (DM), obesity, and dyslipidemia to be an integral part of NAFLD care. Monitoring metabolic biomarkers (glucose, glycosylated hemoglobin [HbA1c], insulin, lipids, and lipoproteins), cardiovascular (CV) risk scores (American College of Cardiology/American Heart Association [ACC/AHA] or Framingham), and subclinical atherosclerosis (coronary artery calcification [CAC], carotid intima-media thickness [CIMT], and carotid plaque) are recommended for risk prediction and reduction. There is no universally accepted treatment for NAFLD, and lifestyle changes with weight loss of at least 10% are the mainstay of management. Combination therapy of ezetimibe and statins have a cardioprotective effect and help reduce liver fat. Despite being an emerging risk factor for CVD and its rapidly increasing pattern affecting a quarter of the global population, NAFLD remains overlooked and undetected, unlike the other traditional risk factors. Hence, we conducted a comprehensive narrative review to shed more light on the importance of screening CVD in NAFLD patients. PubMed indexed relevant articles published from 2002 to 2022 (20 years) were searched in April 2022 using medical subject headings (MeSH) as "nonalcoholic fatty liver disease" [Mesh] AND "cardiovascular diseases" [Mesh]. Evidence from 40 observational studies, three clinical trials, one case series, 45 narrative reviews, four systematic reviews and meta-analyses, three systematic reviews, and one meta-analysis were summarized on the epidemiologic data, pathophysiologic mechanisms, clinical features, diagnostic modalities, overlapping management, perceived challenges and health literacy regarding the CVD risk attributed to NAFLD. |
format | Online Article Text |
id | pubmed-9242599 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-92425992022-07-02 Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease Hassen, Gashaw Singh, Abhishek Belete, Gizeshwork Jain, Nidhi De la Hoz, Ivonne Camacho-Leon, Genesis P Dargie, Nitsuh K Carrera, Keila G Alemu, Tadesse Jhaveri, Sharan Solomon, Nebiyou Cureus Cardiology Nonalcoholic fatty liver disease (NAFLD), also named metabolic dysfunction-associated fatty liver disease (MAFLD), is a progressive disease spectrum encompassing simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. It is a clinically silent disease leading to multiple extra-hepatic complications/comorbidities. It is an independent risk factor for cardiovascular disease (CVD), increasing susceptibility to hypertension, atherosclerosis, arrhythmia, myocardial dysfunction, cardiac valve deformation, and venous thrombosis through putative mechanisms including systemic inflammation, endothelial dysfunction, oxidative stress, insulin resistance, and altered lipid metabolism. Eventually, it increases the CVD prevalence, incident, and fatality, contributing to a huge health care burden. In fact, CVD is becoming the leading cause of mortality among patients with NAFLD. Other cardiometabolic risk factors coexisting with NAFLD may also accelerate the synergistic development of CVD, which warrants assessment targeting hypertension, diabetes mellitus (DM), obesity, and dyslipidemia to be an integral part of NAFLD care. Monitoring metabolic biomarkers (glucose, glycosylated hemoglobin [HbA1c], insulin, lipids, and lipoproteins), cardiovascular (CV) risk scores (American College of Cardiology/American Heart Association [ACC/AHA] or Framingham), and subclinical atherosclerosis (coronary artery calcification [CAC], carotid intima-media thickness [CIMT], and carotid plaque) are recommended for risk prediction and reduction. There is no universally accepted treatment for NAFLD, and lifestyle changes with weight loss of at least 10% are the mainstay of management. Combination therapy of ezetimibe and statins have a cardioprotective effect and help reduce liver fat. Despite being an emerging risk factor for CVD and its rapidly increasing pattern affecting a quarter of the global population, NAFLD remains overlooked and undetected, unlike the other traditional risk factors. Hence, we conducted a comprehensive narrative review to shed more light on the importance of screening CVD in NAFLD patients. PubMed indexed relevant articles published from 2002 to 2022 (20 years) were searched in April 2022 using medical subject headings (MeSH) as "nonalcoholic fatty liver disease" [Mesh] AND "cardiovascular diseases" [Mesh]. Evidence from 40 observational studies, three clinical trials, one case series, 45 narrative reviews, four systematic reviews and meta-analyses, three systematic reviews, and one meta-analysis were summarized on the epidemiologic data, pathophysiologic mechanisms, clinical features, diagnostic modalities, overlapping management, perceived challenges and health literacy regarding the CVD risk attributed to NAFLD. Cureus 2022-05-30 /pmc/articles/PMC9242599/ /pubmed/35783879 http://dx.doi.org/10.7759/cureus.25495 Text en Copyright © 2022, Hassen et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Cardiology Hassen, Gashaw Singh, Abhishek Belete, Gizeshwork Jain, Nidhi De la Hoz, Ivonne Camacho-Leon, Genesis P Dargie, Nitsuh K Carrera, Keila G Alemu, Tadesse Jhaveri, Sharan Solomon, Nebiyou Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease |
title | Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease |
title_full | Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease |
title_fullStr | Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease |
title_full_unstemmed | Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease |
title_short | Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease |
title_sort | nonalcoholic fatty liver disease: an emerging modern-day risk factor for cardiovascular disease |
topic | Cardiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242599/ https://www.ncbi.nlm.nih.gov/pubmed/35783879 http://dx.doi.org/10.7759/cureus.25495 |
work_keys_str_mv | AT hassengashaw nonalcoholicfattyliverdiseaseanemergingmoderndayriskfactorforcardiovasculardisease AT singhabhishek nonalcoholicfattyliverdiseaseanemergingmoderndayriskfactorforcardiovasculardisease AT beletegizeshwork nonalcoholicfattyliverdiseaseanemergingmoderndayriskfactorforcardiovasculardisease AT jainnidhi nonalcoholicfattyliverdiseaseanemergingmoderndayriskfactorforcardiovasculardisease AT delahozivonne nonalcoholicfattyliverdiseaseanemergingmoderndayriskfactorforcardiovasculardisease AT camacholeongenesisp nonalcoholicfattyliverdiseaseanemergingmoderndayriskfactorforcardiovasculardisease AT dargienitsuhk nonalcoholicfattyliverdiseaseanemergingmoderndayriskfactorforcardiovasculardisease AT carrerakeilag nonalcoholicfattyliverdiseaseanemergingmoderndayriskfactorforcardiovasculardisease AT alemutadesse nonalcoholicfattyliverdiseaseanemergingmoderndayriskfactorforcardiovasculardisease AT jhaverisharan nonalcoholicfattyliverdiseaseanemergingmoderndayriskfactorforcardiovasculardisease AT solomonnebiyou nonalcoholicfattyliverdiseaseanemergingmoderndayriskfactorforcardiovasculardisease |